Shetal Patel
Medical Oncology · Chapel Hill, NCNPI 1881988939
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (60.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Genentech, Inc. at 36.2% of the total. Reporting peaked in 2023 at $4,310 and has fallen 54.0% since, to $1,983 in 2025.
Across 14 payments — averaging $458.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$2K
- Hoffmann-la Roche Limited$2K
- Genentech USA, Inc.$2K
- Johnson & Johnson$147
- AbbVie$30
- Merck$16
Across 85 payments — averaging $25,537 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.4M
- Eli Lilly$238K
- Pfizer$186K
- Astrazeneca UK Limited$84K
- Genentech, Inc.$58K
- Hoffmann-la Roche Limited$57K
- plus $180K from 7 others
What the payments were for
- Consulting fees$1,66326%
- Travel & lodging$3,85060%
- Food & beverage$85113%
- Education$531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 4 | $2,324 |
| Hoffmann-la Roche Limited | 3 | $1,987 |
| Genentech USA, Inc. | 4 | $1,913 |
| Johnson & Johnson | 1 | $147 |
| AbbVie | 1 | $30 |
| Merck | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,416 in reported general payments places this provider in the 70th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $20,030 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $11,162 |
| Ondansetron Hcl | 63 | $2,784 |
| Gabapentin | 37 | $2,035 |
| Oxycodone Hcl | 56 | $1,811 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,172 |
| Prochlorperazine Maleate | 62 | $589 |
| Dexamethasone | 32 | $526 |
| Olanzapine | 31 | $207 |
| Calcitriol | 13 | $194 |
| Levothyroxine Sodium | 43 | $127 |
| Triamcinolone Acetonide | 12 | $113 |
| Mirtazapine | 11 | $91 |
| Tamsulosin Hcl | 13 | $41 |
| Amlodipine Besylate | 16 | $27 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Chapel Hill
- Thomas StinchcombeChapel Hill$281K
- Carey AndersChapel Hill$119K
- Natalie GroverChapel Hill$77K
- Elizabeth DeesChapel Hill$14K
- Joannie IvoryChapel Hill$5K
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.